The future of clinical trials is here: the world's first Accelerated Clinical Trials (ACT™) solution.
The Hawthorne Effect ACT™ solution leverages technology, people, and extensive expertise to deliver innovative, accessible, inclusive clinical trials.
Our ACT™ solution combines cutting-edge technology and adaptive processes.
The result is efficient and accurate clinical trials regardless of geography or trial complexity.

Jodi Akin
Founder + CEO
Driven by our dedication to improving the health and well-being of all humanity.
We embrace a dynamic sense of accessibility, accuracy, compassion, and precision in our mission. We are changing the landscape to improve opportunities for patients and the quality and impact of medical research.


Hawthorne Effect enables participation in breakthrough research and clinical trials to improve clinical and commercial outcomes, advance medicine, and bring the patient-clinician relationship back home.

It Will Take More Than Technology to Bridge Clinical Research and Consumer Healthcare
Technology is an enabler, but the solution is one that combines tech with people to normalize research as a standard part of their healthcare delivery.

Diversity in Cardiovascular Clinical Trials (and Why it Matters)
Heart disease remains the number one cause of death in the United States, and that cuts across multiple demographic and sociographic groups. Diversity in research is an imperative with practical outcomes.

Looking Ahead in Clinical Research: Patients and Clinicians as Consumers
The intersection of two movements in consumer care and clinical site architecture point the way forward in the continued democratization of clinical research.
Hawthorne Effect is committed to ongoing clinical trials, seeking treatments to improve the health and quality of life for all patients.

Peripheral Arterial Disease
Evaluating the safety and effectiveness of the ESIPIRT™ Bioresorbable stent.

Kidney Transplant
Exploring the efficacy and safety of NPC-21 to combat CMV infection in transplant recipients.